Pharma channel feed

FDA ap­proves Mod­er­na's RSV vac­cine, mark­ing its sec­ond com­mer­cial prod­uct

Last year
FDA+

#AS­CO24: No­var­tis' new CML treat­ment tops old­er drugs, in­clud­ing Gleevec, in Phase 3 tri­al

Last year
R&D

#AS­CO24: Gilead presents more da­ta on failed Trodelvy lung can­cer study

Last year
R&D

Gilead’s block­buster ADC Trodelvy fails blad­der can­cer con­fir­ma­to­ry study

Last year
R&D
FDA+

No­vo Nordisk mounts le­gal cam­paign against com­pa­nies mar­ket­ing com­pound­ed semaglu­tide

Last year
Law

Lab group sues FDA over fi­nal rule reg­u­lat­ing lab­o­ra­to­ry-de­vel­oped tests

Last year
FDA+

Bris­tol My­er­s' CAR-T ther­a­py Breyanzi adds new ap­proval in man­tle cell lym­phoma

Last year
Cell/Gene Tx
FDA+

Doc­tors who en­dorse drugs on so­cial me­dia are of­ten com­pen­sat­ed, JA­MA study finds

Last year
FDA+

No­var­tis ends de­vel­op­ment of KRAS drug, cit­ing 'in­creas­ing op­tions avail­able'

Last year
R&D

FDA ap­proves Tris Phar­ma's non-stim­u­lant pe­di­atric AD­HD liq­uid med­ica­tion

Last year
FDA+

Lil­ly's Retev­mo lands new ac­cel­er­at­ed ap­proval for pe­di­atric can­cers

Last year
FDA+

Com­pa­ny de­vel­op­ing video games for AD­HD an­nounces sale

Last year
Deals

BioN­Tech to in­crease mR­NA vac­cine foot­print in Africa with $145M in­vest­ment

Last year

Am­gen nabs FDA ap­proval for first Soliris in­ter­change­able biosim­i­lar

Last year
FDA+

Mer­ck re­turns to lu­cra­tive eye dis­ease mar­ket in up to $3B deal for Eye­Bio

Last year
Startups
Deals

NIH-fund­ed tri­als of­ten miss di­ver­si­ty tar­gets, small study shows

Last year
FDA+

NIH of­fi­cials used per­son­al emails, tweaked words to skirt FOIA search­es dur­ing pan­dem­ic, law­mak­ers find

Last year
FDA+
Coronavirus

GLP-1 pre­scrip­tions reach all-time high as Lil­ly and No­vo scram­ble to keep pace with de­mand

Last year
Manufacturing

Louisiana gov­er­nor signs law lim­it­ing abil­i­ty of doc­tors to pre­scribe abor­tion med­ica­tions

Last year
Law

J&J makes an­oth­er I&I ac­qui­si­tion with $1.25B deal for Num­ab's Yel­low Jer­sey

Last year
Deals

Gilead forms pact with Car­tog­ra­phy to map new tar­gets for can­cer drugs

Last year
Startups
Deals

Start­up Hims has long-term plans for cus­tom weight loss shots

Last year
Health Tech

FDA de­nies Ipsen's cit­i­zen pe­ti­tion for block­buster drug So­mat­u­line

Last year
FDA+

No­vo re­ports 're­al­ly pow­er­ful' car­dio, death risk re­duc­tion for semaglu­tide in kid­ney dis­ease

Last year
R&D
First page Previous page 53545556575859 Next page Last page
A service from the Financial Times